Koninklijke Philips NV vs Toro Company (The) Common Stock — how do they compare? Koninklijke Philips NV trades at $25.28 (market cap $24.24B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.27B). The key difference: Koninklijke Philips NV is far larger — about 2.6× Toro Company (The) Common Stock's market cap, and Koninklijke Philips NV pays the higher dividend (4.07%). Which is the better fit depends on your goals — on Pluang, investors hold Koninklijke Philips NV for 84 Days and Toro Company (The) Common Stock for 0 Days on average.
| PHG | TTC | |
|---|---|---|
Market Cap | $24.24B | $9.27B |
Volume | 982,766 | 688,325 |
Sector | Health | Industrials |
52-Week High | $32.91 | $101.76 |
52-Week Low | $23.81 | $67.99 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $30.57B | $10.17B |
Dividend Yield | 4.07% | 1.59% |
Signals from Pluang's Aura AI — not financial advice
PHG trades at $24.89, up 0.61% with a bullish technical signal despite mixed momentum indicators. The company shows strong earnings momentum with three consecutive quarterly beats and a return to profitability in 2025 after previous losses. Recent developments include new product launches in healthcare technology and a $33.7 million ARPA-H award for AI-enabled stroke care. Valuation metrics appear reasonable with P/E of 19.49 and P/S of 1.22.
The outlook remains cautiously optimistic with improving fundamentals but faces execution risks in a competitive healthcare technology market. Analyst consensus leans Hold (63.64%) with no Sell ratings, suggesting stable but not aggressive growth expectations. Key risks include cybersecurity vulnerabilities highlighted by recent hacking incidents and the need to maintain innovation leadership against larger competitors.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →